MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on February 27, 2006; DOI: 10.1124/mol.105.021147


0026-895X/06/6906-1931-1937$20.00
Mol Pharmacol 69:1931-1937, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Erratum
Right arrow An erratum has been published
Right arrow All Versions of this Article:
mol.105.021147v1
69/6/1931    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martin-Moutot, N.
Right arrow Articles by Van Renterghem, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin-Moutot, N.
Right arrow Articles by Van Renterghem, C.

Phoneutria nigriventer Toxin 1: A Novel, State-Dependent Inhibitor of Neuronal Sodium Channels That Interacts with µ Conotoxin Binding Sites

Nicole Martin-Moutot, Pascal Mansuelle1, Gisèle Alcaraz, Raquel Gouvêa Dos Santos, Marta N. Cordeiro, Maria Elena De Lima, Michael Seagar, and Catherine Van Renterghem

Institut National de la Santé et de la Recherche Médicale U641 (N.M.-M., G.A., M.S., C.V.R.), Centre National de la Recherche Scientifique Formation de Recherche en Evolution 2738 (P.M.), and Université de la Méditerranée, Institut Fédératif de Recherches 11 (N.M.-M., P.M., G.A., M.S., C.V.R.), Marseille, France; and Laboratório de Radiobiologia, Comissão Nacional de Energia Nuclear–CNEN/CDTN (R.G.D.S.), Fundação Ezequiel Dias (M.N.C.), and Departamento de Bioquímica e Imunologia, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais (M.E.D.L.), Belo Horizonte, Brazil

A toxin was purified to homogeneity from the venom of the South American armed spider Phoneutria nigriventer and found to have a molecular mass of 8600 Da and a C-terminally amidated glycine residue. It appears to be identical to Toxin 1 (Tx1) isolated previously from this venom. Tx1 reversibly inhibited sodium currents in Chinese hamster ovary cells expressing recombinant sodium (Nav1.2) channels without affecting their fast biophysical properties. The kinetics of inhibition of peak sodium current varied with membrane potential, with on-rates increasing and off-rates decreasing with more depolarized holding potentials in the –100 to –50 mV range. Thus, the apparent affinity of Tx1 for the channel increases as the membrane is depolarized. A mono[125I]iodo-Tx1 derivative displayed high-affinity binding to a single class of sites (KD = 80 pM, Bmax = 0.43 pmol/mg protein) in rat brain membranes. Solubilized binding sites were immunoprecipitated by antibodies directed against a conserved motif in sodium channel {alpha} subunits. 125I-Tx1 binding was competitively displaced by µ conotoxin GIIIB (IC50 = 0.5 µM) but not by 1 µM tetrodotoxin. However, the inhibition of 125I-Tx1 binding by µ conotoxin GIIIB was abrogated in the presence of tetrodotoxin (1 µM). Patch-clamp and binding data indicate that P. nigriventer Tx1 is a novel, state-dependent sodium-channel blocker that binds to a site in proximity to pharmacological site 1, overlapping µ conotoxin but not tetrodotoxin binding sites.


Received November 25, 2005; accepted February 27, 2006

Address correspondence to: Dr. C. Van Renterghem, INSERM U 641, Faculté de Médecine Secteur Nord, Bd Pierre Dramard, F-13916 Marseille, cedex 20, France. E-mail: vanr.c{at}jean-roche.univ-mrs.fr







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics